Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | DTYMK | P23919 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | EIF4E | P06730 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14242232 | 0.84 | TSHR (0.36) | TSHRALDH1A1TDP1HTTMAPT | |
| SCHEMBL1527614 | 0.80 | CHEK1 (0.37) | TSHRALDH1A1TDP1HTTMAPT | |
| SCHEMBL753662 | 0.79 | TSHR (0.38) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL12262070 | 0.78 | TSHR (0.46) | TSHRALDH1A1TDP1CYP3A4ALOX15 | |
| SCHEMBL335434 | 0.76 | MAPT (0.50) | TSHRALDH1A1HTTMAPTPKM | |
| SCHEMBL3710683 | 0.76 | GSK3B (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL12574256 | 0.74 | PKM (0.49) | TSHRALDH1A1TDP1EIF4ETP53 | |
| SCHEMBL4584288 | 0.71 | TSHR (1.00) | TSHRALDH1A1ALOX15GPR35MAPT | |
| SCHEMBL17886205 | 0.71 | CYP1A2 (0.41) | TSHRALDH1A1TDP1CYP3A4HTT | |
| SCHEMBL28018641 | 0.70 | ALDH1A1 (0.45) | ALDH1A1CYP3A4HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530294-B | Aryl diamine immobilized linker, precursor thereof, preparation method and application | 浙江大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20170121349-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2017-05-04 | — | — | US | disclosed |
| WO-2015193506-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-12-23 | — | — | WO | disclosed |
| CN-103827100-B | For reducing [1,2,4] thiadiazine 1,1-dioxide compound of serum uric acid | ANADYS PHARMACEUTICALS, INC. (US) | 2015-08-12 | — | — | CN | disclosed |
| CN-103827100-A | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | ANADYS PHARMACEUTICALS INC | 2014-05-28 | — | — | CN | disclosed |
| CN-102316871-A | [1,2,4]thiadiazine 1,1-dioxide compounds | ANADYS PHARMACEUTICALS INC | 2012-01-11 | — | — | CN | disclosed |
| US-20110065698-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065698-A1 | NOVEL PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065698-A1 | NOVEL PROTEIN KINASE MODULATORS | PIM2, PIM1, PIM3 | TSHR 3026/4885ALDH1A1 4208/4885TDP1 1173/4885 |
| US-20170121349-A1 | Anti-Infective Compounds | FNTB, LSS, PGLS | TSHR 2507/4885ALDH1A1 1595/4885TDP1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.